Psoriasis: which therapy for which patient: focus on special populations and chronic infections
SB Kaushik, MG Lebwohl - Journal of the American Academy of …, 2019 - Elsevier
Despite the availability of several new systemic agents for psoriasis treatment, choosing the
right therapy in certain patient populations can be challenging. There are few up-to-date …
right therapy in certain patient populations can be challenging. There are few up-to-date …
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics
YM Chiu, DY Chen - Expert Review of Clinical Immunology, 2020 - Taylor & Francis
Introduction: Despite the therapeutic effectiveness of biologics targeting immune cells or
cytokines in patients with inflammatory arthritis, which reflects their pathogenic roles, an …
cytokines in patients with inflammatory arthritis, which reflects their pathogenic roles, an …
Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis
T Torres, L Puig - American Journal of clinical dermatology, 2018 - Springer
Psoriasis is a chronic immune-mediated disease associated with several co-morbidities and
negative impacts on a patient's quality of life. Despite the advances in biologic therapy, there …
negative impacts on a patient's quality of life. Despite the advances in biologic therapy, there …
HIV‐associated psoriasis: epidemiology, pathogenesis, and management
People living with HIV (PLWH) are affected by a higher incidence skin disorders, which are
often associated with high morbidity and mortality. In particular, psoriasis affects PLWH …
often associated with high morbidity and mortality. In particular, psoriasis affects PLWH …
Novel therapeutic approaches to psoriasis and risk of infectious disease
A Motolese, M Ceccarelli, L Macca, F Li Pomi… - Biomedicines, 2022 - mdpi.com
Psoriasis is a chronic immune-mediated skin and joint disease, with a plethora of
comorbidities, characterized by a certain genetic predisposition, and a complex …
comorbidities, characterized by a certain genetic predisposition, and a complex …
Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian …
JLW Lambert, S Segaert, PD Ghislain… - Journal of the …, 2020 - Wiley Online Library
Background Psoriasis patients carry an increased risk for associated comorbidities.
Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis …
Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis …
COVID‐19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care …
C Mugheddu, L Pizzatti, S Sanna, L Atzori… - Journal of the …, 2020 - ncbi.nlm.nih.gov
We report a patient with erythrodermic psoriasis, with contraindication to most treatments
because of a recurrent brain oligodendroglioma, who was under apremilast therapy while …
because of a recurrent brain oligodendroglioma, who was under apremilast therapy while …
Managing psoriasis in patients with HBV or HCV infection: practical considerations
S Piaserico, F Messina, FP Russo - American Journal of Clinical …, 2019 - Springer
Considered more efficacious and safer than traditional systemic drugs, biologic therapies
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …
Psoriasis in HIV infection: an update
M Alpalhão, J Borges-Costa… - International journal of …, 2019 - journals.sagepub.com
Psoriasis is a prevalent systemic immune-mediated disease with cutaneous manifestations.
In HIV-infected patients, psoriasis may have a higher incidence, present atypical and more …
In HIV-infected patients, psoriasis may have a higher incidence, present atypical and more …